{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=20", "query": { "intervention": "Open-Label Placebo", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 1998, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T17:02:28.268Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02956486", "title": "A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Elenbecestat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 2212, "start_date": "2016-10-20", "completion_date": "2020-01-15", "has_results": true, "last_update_posted_date": "2021-02-03", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 88, "location_summary": "Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Colton", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Imperial", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02956486" }, { "nct_id": "NCT00001086", "title": "A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 300, "start_date": null, "completion_date": "1999-09", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 55, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 32 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001086" }, { "nct_id": "NCT06843239", "title": "Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis (SSc)", "Scleroderma" ], "interventions": [ { "name": "Tibulizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Zura Bio Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2025-02-06", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06843239" }, { "nct_id": "NCT05552157", "title": "A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimers Disease", "Dementia", "Alzheimers Disease, Familial" ], "interventions": [ { "name": "Remternetug (SC)", "type": "DRUG" }, { "name": "Matching Placebo (Remternetug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2024-11-22", "completion_date": "2034-08-30", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 13, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05552157" }, { "nct_id": "NCT03275922", "title": "Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Placebo ZNS", "type": "DRUG" }, { "name": "ZNS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Impax Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 374, "start_date": "2017-11-27", "completion_date": "2020-09-28", "has_results": false, "last_update_posted_date": "2021-01-11", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275922" }, { "nct_id": "NCT01004432", "title": "Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis", "Arthritis, Rheumatoid", "Autoimmune Diseases" ], "interventions": [ { "name": "Golimumab 50 mg SC", "type": "DRUG" }, { "name": "Golimumab 2 mg/kg IV", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 433, "start_date": "2009-12", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004432" }, { "nct_id": "NCT02889809", "title": "Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Fluticasone furoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Short Acting Beta 2 Agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "9 Years", "sex": "ALL", "summary": "5 Years to 9 Years" }, "enrollment_count": 477, "start_date": "2017-07-10", "completion_date": "2021-06-04", "has_results": true, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 18, "location_summary": "Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Homestead", "state": "Florida" }, { "city": "Loxahatchee Groves", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02889809" }, { "nct_id": "NCT07217444", "title": "Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Major Depressive Disorder (MDD)", "Suicidal Ideation", "Hospitalization in Children" ], "interventions": [ { "name": "Transcranial Magnetic Stimulation", "type": "DEVICE" }, { "name": "Transcranial Magnetic Stimulation Sham", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "14 Years to 18 Years" }, "enrollment_count": 60, "start_date": "2025-11-13", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217444" }, { "nct_id": "NCT07366034", "title": "A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibrosing Interstitial Lung Disease" ], "interventions": [ { "name": "Nerandomilast", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 35, "start_date": "2026-07-21", "completion_date": "2031-04-14", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 7, "location_summary": "Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07366034" }, { "nct_id": "NCT07058077", "title": "A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Heterozygous Familial Hypercholesterolemia (HeFH)" ], "interventions": [ { "name": "Enlicitide Decanoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 153, "start_date": "2025-08-21", "completion_date": "2037-01-23", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-20T17:02:28.268Z", "location_count": 8, "location_summary": "Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more", "locations": [ { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07058077" } ] }